Will Ince

579 total citations
13 papers, 437 citations indexed

About

Will Ince is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Will Ince has authored 13 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Will Ince's work include Renal cell carcinoma treatment (4 papers), Renal and related cancers (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Will Ince is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Renal and related cancers (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Will Ince collaborates with scholars based in United Kingdom, United States and Spain. Will Ince's co-authors include William Novotny, Oliver Rosen, Herbert I. Hurwitz, Jing Yi, Vishva M. Dixit, Gretchen Frantz, Dorothy French, Kim Newton, Hartmut Koeppen and David Dornan and has published in prestigious journals such as Cancer Research, Journal of Virology and The Oncologist.

In The Last Decade

Will Ince

11 papers receiving 425 citations

Peers

Will Ince

ONCOL

PRM

VIROL

HEPAT

Christopher Di Simone United States

Bruno Köhler Germany

Anna L. Sukhanova Russia

Emily Chin United States

Maya Isogai Japan

Toshiyuki Morisawa Japan

Rajeev K. Boregowda United States

Rei Ishibashi Japan

Donna Hempel United States

Leyre Silva Spain

Christopher Di Simone United States

Will Ince

274 ×1.1

ONCOL

114 ×0.9

107 ×1.3

PRM

10 ×0.1

VIROL

33 ×0.5

HEPAT

Citations per year, relative to Will Ince Will Ince (= 1×) peers Christopher Di Simone

Countries citing papers authored by Will Ince

Since Specialization

Citations

This map shows the geographic impact of Will Ince's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Will Ince with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Will Ince more than expected).

Fields of papers citing papers by Will Ince

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Will Ince. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Will Ince. The network helps show where Will Ince may publish in the future.

Co-authorship network of co-authors of Will Ince

This figure shows the co-authorship network connecting the top 25 collaborators of Will Ince. A scholar is included among the top collaborators of Will Ince based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Will Ince. Will Ince is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Ince, Will, et al.. (2024). Squamous cell carcinoma of the oral cavity, oropharynx and upper oesophagus. Medicine. 52(3). 130–135. 1 indexed citations

Blackmur, James P., James N. Armitage, James O. Jones, et al.. (2024). ‘Case of the Month’ from Addenbrooke's Hospital, Cambridge, UK : surgery after near complete response to combined immunotherapy and tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma with inferior vena cava tumour thrombus. British Journal of Urology. 136(4). 613–616.

Tadross, John A., et al.. (2024). Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives. Future Oncology. 20(23). 1695–1711.

Arranz, José Ángel, Omi Parikh, Laura-Maria Krabbe, et al.. (2024). Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis. Current Oncology Reports. 26(12). 1639–1650. 1 indexed citations

Jones, James O., Will Ince, Sarah J. Welsh, & Grant D. Stewart. (2022). Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review. Apollo (University of Cambridge). 6(4). 221–236. 3 indexed citations

Ince, Will & Tim Eisen. (2021). Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?. Expert Opinion on Investigational Drugs. 30(12). 1221–1229. 5 indexed citations

Hill, Ciaran Scott, et al.. (2020). A systematic review of ongoing clinical trials in optic pathway gliomas. Child s Nervous System. 36(9). 1869–1886. 18 indexed citations

Anderson, Jeffrey A., Nancie M. Archin, Will Ince, et al.. (2011). Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4 ⁺ T Cells. Journal of Virology. 85(10). 5220–5223. 74 indexed citations

Hurwitz, Herbert I., Jing Yi, Will Ince, William Novotny, & Oliver Rosen. (2009). The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer. The Oncologist. 14(1). 22–28. 192 indexed citations

10.

Koeppen, Hartmut, Will Ince, Eric Holmgren, et al.. (2004). 150 Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer. European Journal of Cancer Supplements. 2(8). 48–48. 2 indexed citations

11.

Dornan, David, Sheila Bheddah, Kim Newton, et al.. (2004). COP1, the Negative Regulator of p53, Is Overexpressed in Breast and Ovarian Adenocarcinomas. Cancer Research. 64(20). 7226–7230. 110 indexed citations

12.

Eberhard, David A., Lukas C. Amler, Alan D. Goddard, et al.. (2004). 414 Correlation of mutations in EGFR with clinical outcomes in NSCLC patients treated with erlotinib. European Journal of Cancer Supplements. 2(8). 124–124. 1 indexed citations

13.

Bartholomew, C, Walton N. Charles, Carl Saxinger, et al.. (1985). Racial and other characteristics of human T cell leukemia/lymphoma (HTLV-I) and AIDS (HTLV-III) in Trinidad.. BMJ. 290(6477). 1243–1246. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact